Nov. 12 at 3:00 PM
$COGT From SA Article:
Biotechnology company focused on developing precision therapies for genetically defined diseases, Cogent Biosciences (COGT) priced its previously announced underwritten public offering of ~9.68M shares at
$31.00 per share and its underwritten public offering of
$200M of 1.625% convertible senior notes due 2031.
The equity offering was upsized from the previously announced offering size of
$200M.
Net proceeds from the equity offering and the convertible notes will be ~
$475.3M.
